Industry N Nature Medicine
Industry headlines from across biotech and life sciences, gathered from the industry press and linked straight to the publisher. Every story links straight to its publisher.
Industry N Nature Medicine
Industry N Nature Medicine
Industry
Nature Biotechnology
Industry
BioCentury
BIOCENTURY | FINANCEBIOTECH MARKETS: PAUSE BEFORE THE STORM? A BIOCENTURY PODCASTPlus: Cardiovascular trials check and PhRMA vs. GLOBE
Industry
BioCentury
BIOCENTURY | POLITICS, POLICY & LAWOVERTON CONFIRMATION BATTLING CLOCK, ABORTION POLITICSSen. Hawley’s concerns about FDA study of mifepristone safety add complexity to tight confirmation window
Industry
BioCentury
BIOCENTURY | DEALSVIATRIS ADDS ANALGESICS, PIPELINE VIA PACIRA TAKEOUT: DEALS REPORTPlus: Regional deal between Biohaven and Ono; and more
Industry
GEN
Caribou has halted trials of vispacabtagene regedleucel (vispa-cel, formerly CB-010) a treatment for relapsed or refractory B cell non-Hodgkin lymphoma; and of CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of patients with r/r multiple myeloma. The post Sto…
Industry A Applied Clinical Trials
How a phased CRO partnership built on ICH E6(R2) and E6(R3) principles supported a multi-indication biotech portfolio.
Industry
C&EN Pharmaceuticals
The start-up brings a diagnostic-therapeutic combination strategy to small molecules for cancer
Industry
Clinical Trials Arena
Closing the data gap with inclusionary research and educating investors on the promise of women’s health innovations remain key steps to health equity. The post Women’s health landscape shifting, but systemic hurdles remain appeared first on Clinical Trials Arena.
Industry
Fierce Pharma
Signal or Noise? Building Confidence in Launch Decisions Through Trusted Data scox Mon, 10/12/2026 - 12:37 Tue, 12/08/2026 - 13:00 Resource Type Webinar Melanie Conboy, PharmD, MPH Even the most carefully developed launch strategy is built on assumptions. As new clinical evidence…
Industry P Pharmaceutical Commerce
Octapharma USA's Kerem Tokel explains how product value and supply risk should shape freight security, and why complacency remains a persistent gap.
Industry P pharmaphorum
Brent Saunders ejects from Bausch + Lomb once again Phil.Taylor Mon, 12/10/2026 - 16:01
Industry
BioPharma Dive
Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a patient's own cells into dopamine-producing neurons.
Industry
C&EN Pharmaceuticals
The Scorpion Therapeutics spin-off is going after proteins involved in cancer and other diseases
Industry
BioPharma Dive
Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.
Industry P Pharmaceutical Commerce
At LogiPharma USA 2026, Cold Chain Technologies' Vijay Paliwal explains how manufacturers should choose between reusable, single-use and active packaging.
Industry V Virological
September 24, 2026 - Report 1: Genomic characterization of the 2026 Bundibugyo virus disease outbreak in the Democratic Republic of the Congo This report was prepared by Tony Wawina-Bokalanga, Eddy Lusamaki, Tania Bishola Tshitenge, Dav M Ebengo, Jonathan Pekar, Ciara Judge, Bern…
Industry
TechCrunch Biotech and Health
Ultrahuman and Abu Dhabi will spend the next two years working on research and clinical validation of the model.
Industry
TechCrunch Biotech and Health
Tomorrow at 8 a.m. PT, it all begins. 10,000+ founders, investors, and tech operators will gather at San Francisco’s Moscone West for TechCrunch Disrupt 2026 for three days of ideas, connections, and startups shaping what comes next. This is your last 24 hours to secure tick…
Industry P PLOS Biology
by Zhiru Liu, Benjamin H. Good The ratio of nonsynonymous to synonymous substitutions (dN/dS) encodes important information about the selection pressures acting on protein-coding genes. In bacterial populations, dN/dS often declines with the sequence divergence between strains, b…
Industry P PLOS Biology
by Charles ffrench-Constant The consequences of oligodendrocyte involvement in Alzheimer’s disease are poorly understood. Could a key role of gray-matter oligodendrocytes—activity-dependent adaptive myelination to sustain changes in activity—be perturbed, leading to cognitive los…
Industry P PLOS Biology
by Abigail M. Potton, Iana Kalinina, Gordon D. Brown, Maria Makarova, Sandra Catania, Dora E. Corzo-Leon, Elizabeth R. Ballou Fungal morphogenesis is a major driver of disease outcome. For the opportunistic fungal pathogen Cryptococcus neoformans, extreme morphological heterogene…
Industry
MedTech Dive
A software issue can delay use of the Lumify diagnostic ultrasound system in environments without access to Wi-Fi or cellular signal.
Industry P pharmaphorum
BMS eyes filings for idiopathic pulmonary fibrosis drug Phil.Taylor Mon, 12/10/2026 - 13:45
Industry
PharmaVoice
The large pharma’s promising new candidate retatrutide is still in the clinic. But Lilly is already fighting a web of illicit sellers for the drug online.
Industry P Pharmaceutical Executive
Thomas Appio has been named interim CEO of Bausch + Lomb, a move coinciding with an expected upward revision to the company’s full-year guidance.
Industry P Practical Fragments
The list of technologies used to find and validate fragments is long, with more than a dozen in our 2024 poll. But it’s always fun to learn about new approaches. At the Novalix conference earlier this year I learned of “focal molography,” and this is the topic of a recent pa…
Industry P Pharmaceutical Commerce
As HCPs turn to AI tools for clinical answers, pharma brands must optimize for share of answer over share of voice and speed up data operations.
Industry V Virological
Temporal and Phylodynamic analyses of the 2026 Bundibugyo virus disease outbreak in the Democratic Republic of the Congo Institut National de Recherche Biomédicale (INRB), Kinshasa – DRC and partners Context On 15 May 2026, the Ministry of Public Health, Hygiene and Social Welfar…
Industry P pharmaphorum
UK’s next pricing and access scheme to last for 7 years Nicole.Raleigh Mon, 12/10/2026 - 13:04
Industry
Labiotech
Known for its freezing winters, Finland is warming up to global entrepreuners and investors to boost its life science industry. The post Different clusters in different regions: what’s life sciences in Finland like? appeared first on Labiotech.eu. © Labiotech UG and Labiote…
Industry
BioPharma Dive
Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.
Industry
BioSpace
Starting next year, GSK plans to demolish existing buildings and construct new facilities to support clinical and commercial supply. The investment will create more than 300 new jobs over the next five years, Pennsylvania state officials said.
Industry P pharmaphorum
MSD data reveal undercuts eye drug remigromig's potential Phil.Taylor Mon, 12/10/2026 - 11:05
Industry P pharmaphorum
One year after MFN: How US policy is reshaping the global pharma model Nicole.Raleigh Mon, 12/10/2026 - 10:18
Industry P Pharmafile
Symbiosis Pharmaceutical Services has further strengthened its commercial team with three new appointments. Payal Roychoudhury and Joaquín Pérez Fornieles join the Business Development team supporting growth respectively in APAC and Southern Europe and Annie Shafran joins a…
Industry P pharmaphorum
Medtech's digital experience is ready for an upgrade Nicole.Raleigh Mon, 12/10/2026 - 09:49
Industry
European Biotechnology
Finnish biotech Desentum has raised €28 million in an oversubscribed equity round to advance three allergy immunotherapy programs, with Phase 2 results for its lead birch pollen candidate expected before year-end. The post Desentum secures €28M for faster allergy immunotherapy ap…
Industry
Pharmaceutical Technology
Perceptive Discovery and Nucleus RadioPharma have announced a non-exclusive strategic partnership to assist radiopharmaceutical developers shift from initial target validation through to clinical manufacturing.